ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2180

Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner

Akilan Krishnamurthy1, Jitong Sun2, Alexandra Circiumaru1, Yogan Kisten1, Koji Sakuraba3, Thuy Tran1, Peter Damberg1, Patrik Jarvoll1, Li Lu1, Katalin Sándor1, Tunhe Zhou4, vivianne malmström1, Camilla I. Svensson1, Aase Hensvold1, Anca Catrina1, Lars Klareskog1 and Bence Réthi1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Solna, Sweden, 3Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, 4Stockholm University, Stockholm, Sweden

Meeting: ACR Convergence 2022

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Bone Resorption, Inflammation, pain, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: RA – Animal Models

Session Type: Abstract Session

Session Time: 3:00PM-4:00PM

Background/Purpose: The appearance of anti-citrullinated protein antibodies (ACPAs) in the circulation represents a major risk factor for developing rheumatoid arthritis (RA). Here we studied whether a combination of two monoclonal ACPAs could induce pain, bone erosion and tenosynovitis in mice, i.e. symptoms that often precede disease onset in ACPA-positive individuals at risk of developing RA. ACPAs often cross-react with other types of protein-modifications and therefore we evaluated the role of protein citrullination, mediated by peptidyl arginine deiminase (PAD4), in the symptoms observed in ACPA-injected mice.

Methods: Monoclonal ACPAs (1325:04C03 and 1325:01B09), generated from plasma cells of RA patients, were transferred to wildtype and PAD4-deficient mice. ACPA distribution was studied by using positron emission tomography (PET). Pain-like behavior and macroscopic inflammation were monitored for a period of four weeks, followed by the analyses of tenosynovitis in the ankle joints using 9.4T magnetic resonance imaging (MRI) and bone micro-architecture in the tibia using X-ray microscope. Microscopic changes in the tendon sheath were analyzed in decalcified ankle joint sections.

Results: Clone 1325:04C03 accumulated in the smaller joints at higher levels as compared to 1325:01B09 or to control antibodies, in line with the different fine-specificity pattern of the two ACPAs and the preferential targeting of osteoclasts and their precursors by 1325:04C03. The combination of the two ACPA clones induced long-lasting pain-like behavior and trabecular bone loss in mice. Although no synovitis was observed macroscopically, we detected tenosynovitis in the ACPA-injected mice by MRI. Microscopic analyses of the joints revealed a cellular hyperplasia and a consequent enlargement of the tendon sheath in the ACPA-treated group. In PAD4-deficient mice the effects of ACPAs on pain-like behavior, tenosynovitis and bone loss were significantly reduced.

Conclusion: Monoclonal ACPAs can reach the joints from the circulation and induce pain, bone erosion and tenosynovitis via mechanisms dependent on PAD4-mediated citrullination. ACPAs might thus directly contribute to early symptoms preceding the onset of RA.


Disclosures: A. Krishnamurthy, None; J. Sun, None; A. Circiumaru, None; Y. Kisten, None; K. Sakuraba, None; T. Tran, None; P. Damberg, None; P. Jarvoll, None; L. Lu, None; K. Sándor, None; T. Zhou, None; v. malmström, Eli Lilly, Pfizer, Janssen; C. Svensson, Eli Lilly, AstraZeneca, Novartis, UCB, Oblique, Cellectricon; A. Hensvold, None; A. Catrina, Bristol-Myers Squibb, Pfizer; L. Klareskog, None; B. Réthi, None.

To cite this abstract in AMA style:

Krishnamurthy A, Sun J, Circiumaru A, Kisten Y, Sakuraba K, Tran T, Damberg P, Jarvoll P, Lu L, Sándor K, Zhou T, malmström v, Svensson C, Hensvold A, Catrina A, Klareskog L, Réthi B. Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/transfer-of-monoclonal-acpas-induces-pain-bone-loss-and-tenosynovitis-in-mice-in-a-peptidyl-arginine-deiminase-4-dependent-manner/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transfer-of-monoclonal-acpas-induces-pain-bone-loss-and-tenosynovitis-in-mice-in-a-peptidyl-arginine-deiminase-4-dependent-manner/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology